These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33796258)

  • 41. A Review of the Rational and Current Evidence on Colchicine for COVID-19.
    Ghaith HS; Gabra MD; Nafady MH; Elshawah HE; Negida A; Mushtaq G; Kamal MA
    Curr Pharm Des; 2022; 28(39):3194-3201. PubMed ID: 34895117
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Current Status of Baricitinib as a Repurposed Therapy for COVID-19.
    Saber-Ayad M; Hammoudeh S; Abu-Gharbieh E; Hamoudi R; Tarazi H; Al-Tel TH; Hamid Q
    Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358107
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analyzing the impact of machine learning and artificial intelligence and its effect on management of lung cancer detection in covid-19 pandemic.
    Boddu RSK; Karmakar P; Bhaumik A; Nassa VK; Vandana ; Bhattacharya S
    Mater Today Proc; 2022; 56():2213-2216. PubMed ID: 34877264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic.
    Unger JM; Xiao H; LeBlanc M; Hershman DL; Blanke CD
    JAMA Netw Open; 2021 Jul; 4(7):e2118433. PubMed ID: 34323986
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A machine learning and network framework to discover new indications for small molecules.
    Gilvary C; Elkhader J; Madhukar N; Henchcliffe C; Goncalves MD; Elemento O
    PLoS Comput Biol; 2020 Aug; 16(8):e1008098. PubMed ID: 32764756
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predicting missed health care visits during the COVID-19 pandemic using machine learning methods: evidence from 55,500 individuals from 28 European countries.
    Reuter A; Smolić Š; Bärnighausen T; Sudharsanan N
    BMC Health Serv Res; 2023 May; 23(1):544. PubMed ID: 37231416
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utilizing clinical pharmacology in the drug repurposing arena: a look into COVID-19.
    Ruggiero R; Balzano N; Di Napoli R; Sullo MG; Rossi F; Capuano A; Rafaniello C
    Expert Rev Clin Pharmacol; 2022 Oct; 15(10):1225-1231. PubMed ID: 36196903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combating devastating COVID-19 by drug repurposing.
    Pawar AY
    Int J Antimicrob Agents; 2020 Aug; 56(2):105984. PubMed ID: 32305589
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Computational pharmacology: New avenues for COVID-19 therapeutics search and better preparedness for future pandemic crises.
    Kanapeckaitė A; Mažeikienė A; Geris L; Burokienė N; Cottrell GS; Widera D
    Biophys Chem; 2022 Nov; 290():106891. PubMed ID: 36137310
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Machine-learning repurposing of DrugBank compounds for opioid use disorder.
    Feng H; Jiang J; Wei GW
    Comput Biol Med; 2023 Jun; 160():106921. PubMed ID: 37178605
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?
    Vela JM
    Front Pharmacol; 2020; 11():582310. PubMed ID: 33364957
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Network-based drug repurposing for the treatment of COVID-19 patients in different clinical stages.
    Wang X; Wang H; Yin G; Zhang YD
    Heliyon; 2023 Mar; 9(3):e14059. PubMed ID: 36855680
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.
    Gurwitz D
    Drug Dev Res; 2020 Nov; 81(7):777-781. PubMed ID: 32420637
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.
    Alam S; Kamal TB; Sarker MMR; Zhou JR; Rahman SMA; Mohamed IN
    Front Pharmacol; 2021; 12():659577. PubMed ID: 34220503
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benchmarking of Machine Learning classifiers on plasma proteomic for COVID-19 severity prediction through interpretable artificial intelligence.
    Dimitsaki S; Gavriilidis GI; Dimitriadis VK; Natsiavas P
    Artif Intell Med; 2023 Mar; 137():102490. PubMed ID: 36868685
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.
    Mslati H; Gentile F; Perez C; Cherkasov A
    J Chem Inf Model; 2021 Aug; 61(8):3771-3788. PubMed ID: 34313439
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Learning from COVID-19 related trial adaptations to inform efficient trial design-a sequential mixed methods study.
    Chatters R; Cooper CL; O'Cathain A; Murphy C; Lane A; Sutherland K; Burton C; Cape A; Tunnicliffe L
    BMC Med Res Methodol; 2022 Apr; 22(1):128. PubMed ID: 35488193
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Building an OMOP common data model-compliant annotated corpus for COVID-19 clinical trials.
    Sun Y; Butler A; Stewart LA; Liu H; Yuan C; Southard CT; Kim JH; Weng C
    J Biomed Inform; 2021 Jun; 118():103790. PubMed ID: 33887457
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A multimodal deep learning-based drug repurposing approach for treatment of COVID-19.
    Hooshmand SA; Zarei Ghobadi M; Hooshmand SE; Azimzadeh Jamalkandi S; Alavi SM; Masoudi-Nejad A
    Mol Divers; 2021 Aug; 25(3):1717-1730. PubMed ID: 32997257
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient and public involvement prior to trial initiation: lessons learnt for rapid partnership in the COVID-19 era.
    Jamal Z; Perkins A; Allen C; ; Evans R; Sturgess J; Snowdon C; Clayton T; Elbourne D
    Res Involv Engagem; 2021 Mar; 7(1):13. PubMed ID: 33685526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.